

Adam M Brufsky

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1476019/adam-m-brufsky-publications-by-year.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

385
papers

25,400
citations

71
h-index

156
g-index

442
ext. papers

30,348
ext. citations

6.7
avg, IF

8.09
L-index

#	Paper	IF	Citations
385	Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women.. <i>The Lancet Healthy Longevity</i> , 2022 , 3, e54-e66	9.5	2
384	Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	1
383	Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.. <i>Breast Cancer Research and Treatment</i> , 2022 , 192, 153	4.4	1
382	The importance of accessory protein variants in the pathogenicity of SARS-CoV-2.. <i>Archives of Biochemistry and Biophysics</i> , 2022 , 717, 109124	4.1	2
381	Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).. <i>Breast Cancer Research and Treatment</i> , 2022 , 193, 555	4.4	1
380	Abstract OT2-17-01: Randomized, multicenter, international phase 3 ARTEST study to evaluate the efficacy and safety of enobosarm versus active control for the treatment of AR+ ER+ HER2-metastatic breast cancer in patients who progressed on a nonsteroidal aromatase inhibitor, fulvestrant and CDK 4/6 inhibitor. <i>Cancer Research</i> , 2022 , 82, OT2-17-01-OT2-17-01	10.1	
379	Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , 2022 , 82, P5-16-01-P5-16-01	10.1	
378	Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network.. <i>Current Oncology</i> , 2022 , 29, 1047-1061	2.8	0
377	Abstract OT1-14-01: Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2)-expressing cancers, including breast cancer: A phase 1b/2, multicenter, open-label, dose-finding and cohort-expansion study (ZWI-ZW25-204). <i>Cancer Research</i>	10.1	0
376	Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib. <i>Cancer Research</i> , 2022 , 82, PD2-03-PD2-03	10.1	
375	Abstract P2-11-19: Estimating the long-term risk of recurrence in patients receiving HER2-targeted agents in HER2+ early-stage breast cancer (ESBC). <i>Cancer Research</i> , 2022 , 82, P2-11-19-P2-11-19	10.1	
374	Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , 2022 , 82, P5-16-15-P5-16-15	10.1	
373	Abstract P1-18-20: Real-world effectiveness of palbociclib plus letrozole vs letrozole alone for metastatic breast cancer with lung/liver metastases: Flatiron database analysis. <i>Cancer Research</i> , 2022 , 82, P1-18-20-P1-18-20	10.1	
372	Abstract P5-18-02: Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer. <i>Cancer Research</i> , 2022 , 82, P5-18-02-P5-18-02	10.1	
371	Abstract PD15-05: Assessment of estrogen receptor (ESR1) mRNA expression for prediction of extended aromatase inhibitor benefit in HR-positive breast cancer using NRG Oncology/NSABP B-42. <i>Cancer Research</i> , 2022 , 82, PD15-05-PD15-05	10.1	
370	Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial. <i>Cancer Research</i> , 2022 , 82, GS4-10-GS4-10	10.1	0
369	Doxorubicin induced tongue hyperpigmentation. <i>Current Problems in Cancer Case Reports</i> , 2022 , 5, 1001473	4.7	3

368	An issue of concern: unique truncated ORF8 protein variants of SARS-CoV-2.. <i>PeerJ</i> , 2022 , 10, e13136	3.1	1
367	Ongoing Clinical Studies and Future Directions 2022 , 351-370		
366	Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers.. <i>Npj Breast Cancer</i> , 2022 , 8, 51	7.8	0
365	Would New SARS-CoV-2 Variants Change the War against COVID-19?. <i>Epidemiologia</i> , 2022 , 3, 229-237	2.8	0
364	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.. <i>Breast Cancer Research and Treatment</i> , 2022 , 1	4.4	1
363	The structural basis of accelerated host cell entry by SARS-CoV-2 \square <i>FEBS Journal</i> , 2021 , 288, 5010-5020	5.7	73
362	Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. <i>Breast Cancer Research</i> , 2021 , 23, 37	8.3	15
361	Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 2021 , 13, 199-211	3.9	4
360	Voltage-Gated Calcium Channel Antibody-Induced Oropharyngeal Dysphagia Presenting as a Paraneoplastic Neurological Complication in Breast Cancer. <i>Cureus</i> , 2021 , 13, e13677	1.2	
359	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021 , 384, 1529-1541	59.2	108
358	Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and \square prior HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 449-458	4.4	
357	Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era. <i>ACS Nano</i> , 2021 , 15, 8069-8086	16.7	59
356	Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. <i>JAMA Network Open</i> , 2021 , 4, e216322	10.4	2
355	Incorporating HER2/HER3 targeted therapies across solid tumors: Assessing the impact of digital education on clinician practice patterns.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11036-11036	2.2	
354	Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab054	4.6	1
353	Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 536-536	2.2	1
352	Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1020-1020	2.2	5
351	A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. <i>Annals of Oncology</i> , 2021 , 32, 652-660	10.3	17

350	Real-world starting dose and outcomes of palbociclib plus an aromatase inhibitor for metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e13021-e13021	2.2	
349	Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 502-502	2.2	5
348	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). <i>Clinical Cancer Research</i> , 2021 , 27, 5828-5837	12.9	5
347	A unique view of SARS-CoV-2 through the lens of ORF8 protein. <i>Computers in Biology and Medicine</i> , 2021 , 133, 104380	7	23
346	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. <i>Oncologist</i> , 2021 , 26, e1327-e1338	5.7	7
345	Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2021 , 181, 801-809	7.9	25
344	Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. <i>Oncologist</i> , 2021 , 26, e1339-e1346	5.7	5
343	Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management. <i>Frontiers in Endocrinology</i> , 2021 , 12, 713700	5.7	5
342	COVID-19 Vaccines and Thrombosis-Roadblock or Dead-End Street?. <i>Biomolecules</i> , 2021 , 11,	5.9	13
341	Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. <i>Journal of Medical Virology</i> , 2021 , 93, 409-415	19.7	78
340	Magee Equations and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study. <i>Modern Pathology</i> , 2021 , 34, 77-84	9.8	4
339	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 390-399	9.7	16
338	Physical activity, cardiorespiratory fitness, and cognitive function in postmenopausal women with breast cancer. <i>Supportive Care in Cancer</i> , 2021 , 29, 3743-3752	3.9	1
337	Questions concerning the proximal origin of SARS-CoV-2. <i>Journal of Medical Virology</i> , 2021 , 93, 1204-1206	6.7	31
336	Potential interventions for SARS-CoV-2 infections: Zinc showing promise. <i>Journal of Medical Virology</i> , 2021 , 93, 1201-1203	19.7	11
335	Statins and endocrine resistance in breast cancer. 2021 , 4, 356-364		1
334	Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al. <i>Journal of Clinical Oncology</i> , 2021 , 39, 254-255		
333	Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 179-190	4.4	2

332	SARS-CoV-2 research using human pluripotent stem cells and organoids. <i>Stem Cells Translational Medicine</i> , 2021 , 10, 1491-1499	6.9	5
331	Ovarian function suppression as a potential mechanism of chemotherapy. <i>EBioMedicine</i> , 2021 , 70, 103488-9	8.8	0
330	Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice. <i>Targeted Oncology</i> , 2021 , 16, 601-611	5	0
329	A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2021 , 17, 3911-3924	3.6	2
328	The mechanism behind flaring/triggering of autoimmunity disorders associated with COVID-19. <i>Autoimmunity Reviews</i> , 2021 , 20, 102909	13.6	4
327	Implications derived from S-protein variants of SARS-CoV-2 from six continents. <i>International Journal of Biological Macromolecules</i> , 2021 , 191, 934-955	7.9	1
326	Dysregulation of the mevalonate pathway during SARS-CoV-2 infection: An in silico study. <i>Journal of Medical Virology</i> , 2021 , 93, 2396-2405	19.7	5
325	Possible Transmission Flow of SARS-CoV-2 Based on ACE2 Features. <i>Molecules</i> , 2020 , 25,	4.8	21
324	DC/L-SIGNS of hope in the COVID-19 pandemic. <i>Journal of Medical Virology</i> , 2020 , 92, 1396-1398	19.7	33
323	Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. <i>Annals of Oncology</i> , 2020 , 31, 1223-1230	10.3	28
322	Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic. <i>Journal of Medical Virology</i> , 2020 , 92, 2379-2380	19.7	5
321	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. <i>Clinical Cancer Research</i> , 2020 , 26, 1105-1113	12.9	10
320	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , 2020 , 21, 519-530	21.7	159
319	The healthcare value of the Magee Decision Algorithm—use of Magee Equations—and mitosis score to safely forgo molecular testing in breast cancer. <i>Modern Pathology</i> , 2020 , 33, 1563-1570	9.8	17
318	Boning up: amino-bisphosphonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. <i>Journal of Translational Medicine</i> , 2020 , 18, 261	8.5	20
317	Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology. <i>Breast Cancer Research</i> , 2020 , 22, 70	8.3	6
316	Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis. <i>Future Oncology</i> , 2020 , 16, 247-254	3.6	7
315	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion Mutations among Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 2546-2555	12.9	18

314	The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 599-605	4	4
313	Capivasertib inhibits a key pathway in metastatic breast cancer. <i>Lancet Oncology</i> , 2020 , 21, 318-319	21.7	
312	Abstract GS4-01: Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI) 2020 ,		4
311	Abstract P1-19-02: Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice 2020 ,		8
310	Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT Basket Trial 2020 ,		2
309	Abstract P2-20-01: Impact of neratinib on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer (MBC): Findings from the NALA, NEFERT-T, and TBCRC 022 trials 2020 ,		5
308	TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1002-1002	2.2	27
307	Safety and efficacy of single-agent adjuvant trastuzumab in older women with early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 528-528	2.2	1
306	Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS1102-TPS1102	2.2	2
305	Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). <i>Reviews in Cardiovascular Medicine</i> , 2020 , 21, 517-530	3.9	29
304	Ixabepilone efficacy and tolerability in metastatic breast cancer (MBC) patients in a real-world setting.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e13067-e13067	2.2	
303	Assisting decision making on the use of carboplatin for metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e13008-e13008	2.2	
302	Adding precision to 2018 ASCO/CAP HER2 testing guidelines in breast cancer with genomic profiling.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3570-3570	2.2	1
301	The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS7088-TPS7088	2.2	1
300	Adjuvant bisphosphonate therapy in early-stage breast cancer-Treating the soil to kill the seed. <i>Breast Journal</i> , 2020 , 26, 65-68	1.2	1
299	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3138-3149	2.2	150
298	Leveraging Bayesian networks and information theory to learn risk factors for breast cancer metastasis. <i>BMC Bioinformatics</i> , 2020 , 21, 298	3.6	1
297	The Evolving Landscape of HER2-Directed Breast Cancer Therapy. <i>Current Treatment Options in Oncology</i> , 2020 , 21, 82	5.4	12

296	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4274-4282	2.2	92
295	Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. <i>Breast Cancer: Basic and Clinical Research</i> , 2020 , 14, 1178223420944864	2.2	10
294	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 367-374	13.4	59
293	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. <i>Oncologist</i> , 2020 , 25, e214-e222	5.7	15
292	Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. <i>Journal of Medical Economics</i> , 2020 , 23, 37-47	2.4	11
291	Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. <i>Journal of Medical Virology</i> , 2020 , 92, 770-775	19.7	103
290	Distinct viral clades of SARS-CoV-2: Implications for modeling of viral spread. <i>Journal of Medical Virology</i> , 2020 , 92, 1386-1390	19.7	88
289	CDK4/6 inhibitors: taking the place of chemotherapy?. <i>Lancet Oncology, The</i> , 2019 , 20, 1329-1330	21.7	2
288	Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy. <i>Modern Pathology</i> , 2019 , 32, 807-816	9.8	31
287	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 2395-2405	59.2	208
286	Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR/HER2 Advanced Breast Cancer Enrolled in an Expanded Access Program. <i>Clinical Breast Cancer</i> , 2019 , 19, 317-325.e4	3	9
285	Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 321-328	4.4	10
284	A clinical decision support system learned from data to personalize treatment recommendations towards preventing breast cancer metastasis. <i>PLoS ONE</i> , 2019 , 14, e0213292	3.7	20
283	Targeted mutation detection in breast cancer using MammaSeq. <i>Breast Cancer Research</i> , 2019 , 21, 22	8.3	22
282	Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 388-398	9.7	45
281	Artificial intelligence-directed prognostication of breast cancer. <i>EBioMedicine</i> , 2019 , 46, 6-7	8.8	1
280	A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. <i>Breast Cancer Management</i> , 2019 , 8, BMT22	0.7	4
279	A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence. <i>Scientific Reports</i> , 2019 , 9, 14863	4.9	12

278	Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC). <i>Annals of Oncology</i> , 2019 , 30, v854-v855	10.3	6
277	Abstract CT138: NCI-MATCH EAY131 -Z11: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations 2019 ,		6
276	Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1002-1002	2.2	61
275	Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1013-1013	2.2	20
274	A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1057-1057	2.2	16
273	Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 503-503	2.2	1
272	Clinical Trial in Progress: The FLEX Big Data Platform explores new gene expression profiles and investigator-initiated protocols in early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS3155-TPS3155		33
271	Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2019 , 19, 304-310	3	7
270	CACNG2 polymorphisms associate with chronic pain after mastectomy. <i>Pain</i> , 2019 , 160, 561-568	8	11
269	Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. <i>Clinical Cancer Research</i> , 2019 , 25, 2433-2441	12.9	33
268	Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. <i>Molecular Cancer Research</i> , 2019 , 17, 457-468	6.6	22
267	Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues. <i>Breast Cancer Research and Treatment</i> , 2019 , 173, 667-677	4.4	16
266	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 88-99	21.7	58
265	Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer. <i>Biological Research for Nursing</i> , 2019 , 21, 50-60	2.6	1
264	Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Pozitotinib: Case Report of Compassionate Drug Use. <i>Clinical Breast Cancer</i> , 2019 , 19, e7-e11	3	4
263	Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2018 , 149, 332-343	1.9	
262	Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. <i>Annals of Oncology</i> , 2018 , 29, 872-880	10.3	54
261	Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. <i>Oncologist</i> , 2018 , 23, 528-539	5.7	62

260 Bisphosphonates in Early Breast Cancer **2018**, 769-772.e1

259 Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. *Journal of the National Cancer Institute*, **2018**, 110, 9.7 54

258 Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. *Clinical Breast Cancer*, **2018**, 18, e1239-e1245 3 14

257 Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?. *American Journal of Clinical Pathology*, **2018**, 150, 34-42 1.9 26

256 Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. *New England Journal of Medicine*, **2018**, 379, 111-121 59.2 959

255 nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. *Annals of Oncology*, **2018**, 29, 1763-1770 10.3 52

254 Pathologist's health-care value in the triage of Oncotype DX testing: a value-based pathology study of tumour biology with outcomes. *Histopathology*, **2018**, 73, 692-700 7.3 2

253 Outcome of everolimus based therapy in hormone receptor positive metastatic breast cancer patients after progression on palbociclib combination.. *Journal of Clinical Oncology*, **2018**, 36, 1064-1064^{2.2} 1

252 Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer.. *Journal of Clinical Oncology*, **2018**, 36, 12097-12097 2.2 1

251 Dissemination of breast cancer knowledge and expertise from NCI-CCC tumor boards with community oncologists.. *Journal of Clinical Oncology*, **2018**, 36, e18575-e18575 2.2 1

250 TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.. *Journal of Clinical Oncology*, **2018**, 36, LBA1-LBA1 2.2 7

249 Use of cell-free DNA for management of breast and lung cancer by academic and community providers.. *Journal of Clinical Oncology*, **2018**, 36, 12046-12046 2.2

248 Features associated with long-term survival in metastatic breast cancer.. *Journal of Clinical Oncology*, **2018**, 36, e13074-e13074 2.2

247 Racial comparison of income, survival, co-morbidities and Trastuzumab therapy among Her 2+ women with metastatic breast cancer (MBC).. *Journal of Clinical Oncology*, **2018**, 36, e18673-e18673 2.2

246 A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies.. *Journal of Clinical Oncology*, **2018**, 36, TPS1113-TPS1113 2.2

245 Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). *Journal of Clinical Oncology*, **2018**, 36, 2621-2629 2.2 39

244 Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. *Journal of Clinical Oncology*, **2018**, 36, 1556-1563 2.2 93

243 Statin drugs to reduce breast cancer recurrence and mortality. *Breast Cancer Research*, **2018**, 20, 144 8.3 70

242	Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. <i>Scientific Reports</i> , 2018 , 8, 17313	4.9	15
241	Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer. <i>Oncology Nursing Forum</i> , 2018 , 45, 308-326	1.7	11
240	Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. <i>Psycho-Oncology</i> , 2017 , 26, 44-52	3.9	27
239	Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017 , 25, 392-398	1.9	5
238	Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer. <i>Cancer Medicine</i> , 2017 , 6, 339-348	4.8	8
237	Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer. <i>Lancet Oncology, The</i> , 2017 , 18, 428-429	21.7	0
236	Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer. <i>Cancer</i> , 2017 , 123, 2061-2069	6.4	40
235	TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 649-658	4.4	15
234	Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. <i>JAMA Oncology</i> , 2017 , 3, 666-671	13.4	95
233	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. <i>Clinical Cancer Research</i> , 2017 , 23, 2691-2701	12.9	84
232	Higher Radiation Dose to Immune System is Correlated With Poorer Survival in Patients With Stage III Non-small Cell Lung Cancer: A Secondary Study of a Phase 3 Cooperative Group Trial (NRG Oncology RTOG 0617). <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, S151-S152	4	26
231	Alcohol consumption and breast tumor gene expression. <i>Breast Cancer Research</i> , 2017 , 19, 108	8.3	18
230	An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors. <i>Breast Cancer: Targets and Therapy</i> , 2017 , 9, 95-110	3.9	13
229	Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). <i>Journal of Clinical Oncology</i> , 2017 , 35, 2647-2655	2.2	144
228	Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth	2.2	39
227	Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer. <i>Breast Journal</i> , 2017 , 23, 718-722	1.2	8
226	Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017 , 77, 660-666	2	32
225	Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2017 , 3, 28	7.8	8

224	Effect of gastroretentive gabapentin (Gralise) on postmastectomy pain syndrome: a proof-of-principle open-label study. <i>Pain Reports</i> , 2017 , 2, e596	3.5	2
223	The Double-Edged Sword: Controversies in Anthracycline-Based Chemotherapy for Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017 , 9, 210-216	0.8	
222	Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. <i>Cancer Treatment Reviews</i> , 2017 , 59, 22-32	14.4	29
221	Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. <i>Modern Pathology</i> , 2017 , 30, 1078-1085	0.8	22
220	-Paclitaxel for the treatment of breast cancer: an update across treatment settings. <i>Experimental Hematology and Oncology</i> , 2017 , 6, 7	7.8	19
219	TACT2: improving treatment tolerability in early breast cancer. <i>Lancet Oncology, The</i> , 2017 , 18, 843-845	21.7	
218	The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1853-1860	3.1	7
217	Understanding the Needs of Patients with Metastatic Breast Cancer: Results of the Make Your Dialogue Count Survey. <i>Breast Journal</i> , 2017 , 23, 17-25	1.2	12
216	Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. <i>JCI Insight</i> , 2017 , 2,	9.9	77
215	Number of tumor-infiltrating lymphocytes in breast cancer brain metastases compared to matched breast primaries.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2049-2049	2.2	2
214	Incidence of febrile neutropenia with use of docetaxel plus cyclophosphamide (TC) for breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e12073-e12073	2.2	2
213	Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. <i>Oncotarget</i> , 2017 , 8, 66901-66911	3.3	31
212	Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification. <i>Cureus</i> , 2017 , 9, e1434	1.2	9
211	Experience and impact of alopecia in patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 239-239	2.2	
210	Health economic impact of breast cancer index (BCI) in patients with hormone responsive breast cancer (HRBC) considering extended adjuvant endocrine therapy (EET).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 25-25	2.2	1
209	Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2072-2072	2.2	
208	Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3941-3942	2.2	4
207	Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. <i>Clinical Breast Cancer</i> , 2016 , 16, 471-479.e1	3	23

206	Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?. <i>Clinical Cancer Research</i> , 2016 , 22, 4963-4965	12.9	3
205	Exploration of communication gaps among women with metastatic breast cancer, caregivers and oncologists. <i>Breast Cancer Management</i> , 2016 , 5, 151-160	0.7	4
204	Pathways Clinical Decision Support for Appropriate Use of Key Biomarkers. <i>Journal of Oncology Practice</i> , 2016 , 12, e681-7	3.1	9
203	Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory study. <i>SpringerPlus</i> , 2016 , 5, 422		13
202	Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. <i>Lancet, The</i> , 2016 , 387, 849-56	4.0	111
201	Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. <i>Lancet, The</i> , 2016 , 387, 857-65	4.0	53
200	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 1130-7	12.9	144
199	Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HR+, HER2- breast cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1000-1009	2.2	12
198	Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1074-1074	2.2	1
197	Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 501-501	2.2	16
196	HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 612-612	2.2	3
195	COLET (NCT02322814): A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib (C) in combination with paclitaxel (P) as first-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS1100-TPS1100	2.2	2
194	Predictors of trajectories of cognitive change in women with breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 149-149	2.2	
193	Palbociclib's effect on estrogen receptor mutations in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 533-533	2.2	
192	Mitotic index to predict breast cancer recurrence after neoadjuvant systemic therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23265-e23265	2.2	0
191	Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER- disease?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 580-580	2.2	
190	Utilization of Magee equation 3 in ER-positive, HER2-negative/equivocal tumors to determine pathologic response to neoadjuvant therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11594-11594	2.2	
189	Evaluation of the analytical performance of the Breast Cancer Index (BCI) assay.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 540-540	2.2	

188	Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study. <i>Breast Cancer: Targets and Therapy</i> , 2016 , 8, 231-239	3.9	2
187	Beliefs in Chemotherapy and Knowledge of Cancer and Treatment Among African American Women With Newly Diagnosed Breast Cancer. <i>Oncology Nursing Forum</i> , 2016 , 43, 180-9	1.7	11
186	Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 5362-5369	12.9	42
185	Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial. <i>Bone</i> , 2016 , 90, 123-6	4.7	4
184	Is there room for bevacizumab in metastatic breast cancer?. <i>Lancet Oncology, The</i> , 2016 , 17, 1175-6	21.7	2
183	Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. <i>Lancet, The</i> , 2015 , 386, 1353-1361	40	447
182	Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial. <i>Osteoporosis International</i> , 2015 , 26, 1857-64	5.3	31
181	Patterns of change in cognitive function with anastrozole therapy. <i>Cancer</i> , 2015 , 121, 2627-36	6.4	55
180	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2015 , 373, 2005-14	59.2	865
179	Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1037-1048	21.7	115
178	Developing in vitro models of human ductal carcinoma in situ from primary tissue explants. <i>Breast Cancer Research and Treatment</i> , 2015 , 153, 311-21	4.4	16
177	Bisphosphonates, bone, and breast cancer recurrence. <i>Lancet, The</i> , 2015 , 386, 1319-1320	40	11
176	Bisphosphonates in breast cancer. <i>International Journal of Cancer</i> , 2015 , 137, 753-64	7.5	28
175	The effects of Reiki therapy and companionship on quality of life, mood, and symptom distress during chemotherapy. <i>Journal of Evidence-Based Complementary & Alternative Medicine</i> , 2015 , 20, 20-7		8
174	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 575	2.8	20
173	Bisphosphonates do not reduce breast cancer in postmenopausal women. <i>Annals of Internal Medicine</i> , 2015 , 162, JC5	8	
172	Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2015 , 9, 137-47	1.8	10
171	Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. <i>Cancer Medicine</i> , 2015 , 4, 989-94	4.8	39

170	Can circulating tumor cells predict resistance in metastatic breast cancer?. <i>Clinical Cancer Research</i> , 2015 , 21, 2421-3	12.9	9
169	Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40 2015 ,		6
168	Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer 2015 ,		5
167	Expression of high affinity folate receptor in breast cancer brain metastasis. <i>Oncotarget</i> , 2015 , 6, 30327-33		11
166	Prognostic significance of transcription factors FOXA1 and GATA-3 in ductal carcinoma in situ in terms of recurrence and estrogen receptor status. <i>Journal of Cancer Metastasis and Treatment</i> , 2015 , 1, 84	3.8	1
165	Histopathological markers at craniotomy and outcome in breast cancer brain metastases.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2027-2027	2.2	
164	Detection and functional analysis of estrogen receptor mutations (ESR1-mut) in patients with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 554-554	2.2	
163	Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 533-533	2.2	
162	Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS1106-TPS1106	2.2	
161	End-of-life chemotherapy use in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20505-e20505		
160	Doctor-patient perceptions and discourse on side effects related to metastatic breast cancer (MBC) treatment: The Make Your Dialogue Count survey.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20575-e20575	2.2	
159	Metastatic pattern of invasive lobular carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e11561-e11561	2.2	
158	Is Body Mass Index a prognostic factor in early-stage breast cancer patients who subsequently developed metastatic disease?. <i>Journal of Clinical Oncology</i> , 2015 , 33, e12639-e12639	2.2	
157	Emotional experiences of oncologists treating women with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 97-97	2.2	
156	Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. <i>British Journal of Cancer</i> , 2014 , 110, 2756-64	8.7	40
155	Length of chemotherapy and use of bevacizumab for breast cancer. <i>Lancet Oncology</i> , 2014 , 15, 1285-7		
154	Breast cancer: Zoledronic acid--more than just a bone drug. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 564-5	19.4	5
153	Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 725-34	4.4	57

152	The bone substudy of MA.27: does bone make a difference?. <i>Lancet Oncology, The</i> , 2014 , 15, 375-7	21.7	2
151	Current Approaches and Emerging Directions in HER2-resistant Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2014 , 8, 109-18	2.2	17
150	A new method for predicting patient survivorship using efficient bayesian network learning. <i>Cancer Informatics</i> , 2014 , 13, 47-57	2.4	10
149	Metastasis of breast carcinoma to the maxillary sinus. <i>Breast Journal</i> , 2014 , 20, 318-9	1.2	1
148	Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway. <i>Breast Journal</i> , 2014 , 20, 347-57	1.2	2
147	Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014 , 37, 404-10 ^{2.7}	2.7	18
146	Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. <i>Oncology Nursing Forum</i> , 2014 , 41, 274-85	1.7	78
145	Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 500-500	2.2	34
144	Comparison of test results and clinical outcomes of patients assessed with both MammaPrint and Oncotype DX with pathologic variables: An independent study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 550-550	2.2	6
143	Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 569-569	2.2	3
142	tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS1146-TPS1146	2.2	2
141	Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase 2, single-arm, multicenter study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 139-139	2.2	1
140	Persistent pain following breast cancer surgery: Why does it hurt more for some survivors than others?. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20634-e20634	2.2	
139	Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 635-635	2.2	1
138	Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 36-36	2.2	1
137	Understanding potential communication gaps between oncologists and patients with advanced breast cancer: A survey of oncologists.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 124-124	2.2	
136	Effect of tumor subtype on overall survival in brain metastatic breast cancer patients treated with cranial irradiation.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 74-74	2.2	
135	The use of adjuvant bisphosphonates in the treatment of early-stage breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 749-56	0.6	5

134	Using mice to treat (wo)men: mining genetic changes in patient xenografts to attack breast cancer. <i>Cell Reports</i> , 2013 , 4, 1061-2	10.6	1
133	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2013 , 14, 1183-92 ^{21.7}	21.7	268
132	Persistent pain in postmastectomy patients: comparison of psychophysical, medical, surgical, and psychosocial characteristics between patients with and without pain. <i>Pain</i> , 2013 , 154, 660-668	8	113
131	Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. <i>Breast Journal</i> , 2013 , 19, 504-11	1.2	15
130	Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3197-204	2.2	107
129	Treatment of HER2-positive breast cancer: looking backwards briefly. <i>Lancet Oncology</i> , 2013 , 14, 1250-1	21.7	4
128	How to develop and deliver pathway-based care. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 843-50, x	3.1	2
127	Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 461-70	4.4	30
126	Persistent postmastectomy pain in breast cancer survivors: analysis of clinical, demographic, and psychosocial factors. <i>Journal of Pain</i> , 2013 , 14, 1185-95	5.2	123
125	Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. <i>Cancer Treatment Reviews</i> , 2013 , 39, 261-9	14.4	59
124	Breast cancer survivorship symptom management: current perspective and future development. <i>Breast Cancer Management</i> , 2013 , 2, 71-81	0.7	11
123	First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. <i>Oncologist</i> , 2013 , 18, 501-10	5.7	51
122	Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. <i>Clinical Cancer Research</i> , 2013 , 19, 4196-205	12.9	142
121	Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. <i>Oncologist</i> , 2013 , 18, 353-61	5.7	57
120	Does lifetime exposure to hormones predict pretreatment cognitive function in women before adjuvant therapy for breast cancer?. <i>Menopause</i> , 2013 , 20, 922-9	2.5	10
119	An isoform of C/EBP β LIP, regulates expression of the chemokine receptor CXCR4 and modulates breast cancer cell migration. <i>Journal of Biological Chemistry</i> , 2013 , 288, 28656-67	5.4	21
118	Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. <i>Modern Pathology</i> , 2013 , 26, 658-64	9.8	136
117	Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) and entinostat (MS-275) in patients with triple-negative advanced breast cancer. 2013 ,		6

116	Initial results from the 21-gene breast cancer assay registry: A prospective observational study in patients (pts) with ER+, early-stage invasive breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 565-565	2.2	1
115	Efficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumab.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 600-600	2.2	1
114	Prediction of early and late distant recurrence in early-stage breast cancer with Breast Cancer Index.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 594-594	2.2	
113	Prognostic factors and survival of patients with brain metastasis (BM) from breast cancer (BC) who underwent craniotomy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e22017-e22017	2.2	
112	Prognostic factors and survival of patients with brain metastasis (BM) from breast cancer (BC) who underwent craniotomy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 143-143	2.2	
111	Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. <i>Cancer</i> , 2012 , 118, 1192-201	6.4	139
110	Factors associated with mortality after breast cancer metastasis. <i>Cancer Causes and Control</i> , 2012 , 23, 103-12	2.8	84
109	Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. <i>Lancet Oncology</i> , 2012 , 13, 734-42	21.7	144
108	Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term. <i>Breast Cancer Research</i> , 2012 , 14, 308	8.3	2
107	Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?. <i>Breast Cancer Research</i> , 2012 , 14, 213	8.3	20
106	Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 875-83	4.4	46
105	Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. <i>Annals of Oncology</i> , 2012 , 23, 1130-1137	10.3	54
104	Comprehensive molecular portraits of human breast tumours. <i>Nature</i> , 2012 , 490, 61-70	50.4	8025
103	Bevacizumab added to neoadjuvant chemotherapy for breast cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 310-20	59.2	361
102	Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?. <i>Cancer Treatment Reviews</i> , 2012 , 38, 798-806	14.4	67
101	Patient preferences for chemotherapies used in breast cancer. <i>International Journal of Women's Health</i> , 2012 , 4, 279-87	2.8	24
100	Decreased risk of breast cancer associated with oral bisphosphonate therapy. <i>Breast Cancer: Targets and Therapy</i> , 2012 , 4, 75-81	3.9	3
99	Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 1067-75	4.4	82

98	Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3792-9	2.2	361
97	Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment. <i>Clinical Cancer Research</i> , 2012 , 18, 2382-90	12.9	83
96	Reply to A. Kesikli et al. <i>Journal of Clinical Oncology</i> , 2012 , 30, 461-462	2.2	1
95	Comorbidity as a mediator of survival disparity between younger and older women diagnosed with metastatic breast cancer. <i>Hypertension</i> , 2012 , 59, 205-11	8.5	18
94	Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. <i>Clinical Cancer Research</i> , 2012 , 18, 4841-9	12.9	102
93	Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. <i>Clinical Cancer Research</i> , 2012 , 18, 3478-86	12.9	89
92	NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC-paclitaxel (P) plus gemcitabine (G) with DD AC-P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA1000-LBA1000	2.2	7
91	Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA506-LBA506	2.2	21
90	Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 100-100	2.2	4
89	Long-term survivor (LTS) characteristics in HER2+ metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 133-133	2.2	1
88	Driving Evidence-Based Standardization of Care within a Framework of Personalized Medicine. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , e62-5	7.1	0
87	Racial disparities in treatment patterns and clinical outcomes in patients (pts) with HER2+ metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1526-1526	2.2	
86	Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer. <i>Breast Cancer Research</i> , 2011 , 13, R98	8.3	43
85	Adjuvant bisphosphonates for early-stage breast cancer. <i>Lancet Oncology</i> , 2011 , 12, 610-1	21.7	2
84	New antiresorptive agents in metastatic breast cancer: an advance or more of the same?. <i>Community Oncology</i> , 2011 , 8, 61-62		
83	Ixabepilone in advanced breast cancer: clinical, treatment, and cost-related studies. <i>Community Oncology</i> , 2011 , 8, 73-80		
82	Understanding the estrogen receptor signaling pathway: focus on current endocrine agents for breast cancer in postmenopausal women. <i>Community Oncology</i> , 2011 , 8, 343-352		1
81	The beginning of small molecule therapy for endocrine-resistant metastatic breast cancer?. <i>Community Oncology</i> , 2011 , 8, 498-500		

80	Direct interaction between NHERF1 and Frizzled regulates β -catenin signaling. <i>Oncogene</i> , 2011 , 30, 32-42	9.2	38
79	Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. <i>Clinical Breast Cancer</i> , 2011 , 11, 82-92	3	99
78	A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2011 , 11, 211-20	3	26
77	The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 441-6	4.4	42
76	The effect of delays in treatment for breast cancer metastasis on survival. <i>Breast Cancer Research and Treatment</i> , 2011 , 130, 953-64	4.4	28
75	RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1252-60	2.2	779
74	Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article. <i>Journal of Neurosurgery</i> , 2011 , 114, 792-800	3.2	91
73	Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. <i>Annals of Oncology</i> , 2011 , 22, 2546-2555	10.3	139
72	A case of late-onset gemcitabine lung toxicity. <i>Clinical Medicine Insights: Oncology</i> , 2011 , 5, 171-6	1.8	7
71	The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity. <i>Oncology Nursing Forum</i> , 2011 , 38, 85-9	1.7	23
70	Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. <i>Annals of Oncology</i> , 2011 , 22, 1094-1101	10.3	22
69	Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. <i>Clinical Cancer Research</i> , 2011 , 17, 4834-43	12.9	244
68	Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. <i>Modern Pathology</i> , 2011 , 24, 367-74	9.8	41
67	RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4286-93	2.2	322
66	Metastatic breast cancer or multiple myeloma? Camouflage by lytic lesions. <i>Journal of Oncology</i> , 2010 , 2010, 509530	4.5	6
65	CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1496-512	9.7	117
64	Transcatheter arterial chemoembolization is a feasible palliative locoregional therapy for breast cancer liver metastases. <i>International Journal of Surgical Oncology</i> , 2010 , 2010, 251621	0.9	15
63	Understanding and optimizing bone health in breast cancer. <i>Current Medical Research and Opinion</i> , 2010 , 26 Suppl 3, 3-20	2.5	23

62	Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2010 , 10, 281-7	3	75
61	Metastasis and bone loss: advancing treatment and prevention. <i>Cancer Treatment Reviews</i> , 2010 , 36, 615-20	14.4	100
60	Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 186-95	2.7	51
59	The evolving role of bone-conserving therapy in patients with breast cancer. <i>Seminars in Oncology</i> , 2010 , 37 Suppl 1, S12-9	5.5	4
58	Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. <i>Cancer</i> , 2010 , 116, 1431-9	6.4	113
57	Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. <i>Cytometry Part B - Clinical Cytometry</i> , 2010 , 78, 287-301	3.4	51
56	Randomized controlled trial of the Breast Cancer Recovery Program for women with breast cancer-related lymphedema. <i>American Journal of Occupational Therapy</i> , 2010 , 64, 59-72	0.4	41
55	Challenges of illness in metastatic breast cancer: a low-income African American perspective. <i>Palliative and Supportive Care</i> , 2009 , 7, 143-52	2.5	13
54	Small beginnings: do they matter? The importance of lymphovascular invasion in early breast cancer. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 698-9	9.7	1
53	Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. <i>Clinical Breast Cancer</i> , 2009 , 9, 77-85	3	174
52	Adjuvant endocrine therapy for premenopausal women with breast cancer. <i>Breast</i> , 2009 , 18 Suppl 3, S122-30	3.6	27
51	A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2009 , 117, 83-9	4.4	33
50	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 1452-9	12.9	494
49	The Unique Perspective of Illness Among Women With Metastatic Breast Cancer According to Race and Income. <i>Journal of Hospice and Palliative Nursing</i> , 2009 , 11, 27-38	2.2	8
48	Histopathologic variables predict Oncotype DX recurrence score. <i>Modern Pathology</i> , 2008 , 21, 1255-61	9.8	164
47	Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. <i>Modern Pathology</i> , 2008 , 21, 363-8	9.8	41
46	RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2008 , 8, 370-3	3	31
45	Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy. <i>Annals of Oncology</i> , 2008 , 19, 1639-43	10.3	13

44	Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 1721-6	6.7	84
43	Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFACT. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1664-70	2.2	399
42	Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. <i>Oncologist</i> , 2008 , 13, 503-14	5.7	146
41	Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2644-52	2.2	71
40	Practical guidance for the management of aromatase inhibitor-associated bone loss. <i>Annals of Oncology</i> , 2008 , 19, 1407-1416	10.3	182
39	Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. <i>Oncologist</i> , 2008 , 13, 187-95	5.7	59
38	Zoledronic acid for cancer therapy-induced and postmenopausal bone loss. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 1013-28	4	5
37	Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer. <i>Biologics: Targets and Therapy</i> , 2008 , 2, 505-15	4.4	9
36	Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors. <i>Current Oncology Reports</i> , 2008 , 10, 18-26	6.3	9
35	What do perceived cognitive problems reflect?. <i>The Journal of Supportive Oncology</i> , 2008 , 6, 238-42		28
34	Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 829-36	2.2	269
33	Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors. <i>Clinical Breast Cancer</i> , 2007 , 8 Suppl 1, S22-34	3	9
32	Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 131-6	5.6	38
31	Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1232-8	2.2	71
30	Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. <i>Menopause</i> , 2007 , 14, 995-8	2.5	116
29	Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. <i>Seminars in Oncology</i> , 2006 , 33, S13-7	5.5	49
28	Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer. <i>Clinical Breast Cancer</i> , 2006 , 6, 511-7	3	12
27	Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. <i>Cancer</i> , 2006 , 106, 2136-42	6.4	87

26	Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. <i>Journal of Immunology</i> , 2006 , 177, 2717-27	5.3	15
25	Inhibin-B levels in healthy young adult men and prepubertal boys: is obesity the cause for the contemporary decline in sperm count because of fewer Sertoli cells?. <i>Journal of Andrology</i> , 2006 , 27, 560-4		82
24	Cognitive impairment associated with adjuvant therapy in breast cancer. <i>Psycho-Oncology</i> , 2006 , 15, 422-30	3.9	247
23	Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. <i>Archives of Pathology and Laboratory Medicine</i> , 2006 , 130, 1516-21	5	60
22	Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2005 , 6, 247-52	3	43
21	Single-fraction radiosurgery for the treatment of spinal breast metastases. <i>Cancer</i> , 2005 , 104, 2244-54	6.4	113
20	Long-term survivors after gamma knife radiosurgery for brain metastases. <i>Cancer</i> , 2005 , 104, 2784-91	6.4	87
19	Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2726-34	2.2	201
18	Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. <i>Clinical Cancer Research</i> , 2005 , 11, 3385-91	12.9	177
17	The nurse as principal investigator in a pharmaceutically sponsored drug trial: considerations and challenges. <i>Oncology Nursing Forum</i> , 2005 , 32, 293-9	1.7	4
16	Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. <i>Cancer Investigation</i> , 2004 , 22, 858-65	2.1	100
15	The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. <i>Journal of Pain and Symptom Management</i> , 2004 , 27, 185-90	4.8	86
14	Evaluation of the OncoTCap (Oncology Thinking Cap) simulation in teaching medical students about clinical trials: some successes and some surprises. <i>Journal of Cancer Education</i> , 2004 , 19, 149-55	1.8	1
13	Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. <i>Urology</i> , 2003 , 62, 99-104	1.6	18
12	Molecular anatomy of an intracranial aneurysm: coordinated expression of genes involved in wound healing and tissue remodeling. <i>Stroke</i> , 2001 , 32, 1036-42	6.7	117
11	Health care professionals' grief: a model based on occupational style and coping. <i>Psycho-Oncology</i> , 2001 , 10, 187-98	3.9	50
10	Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. <i>Metabolism: Clinical and Experimental</i> , 2001 , 50, 1242-7	12.7	100
9	Oncology thinking cap: scaffolded use of a simulation to learn clinical trial design. <i>Teaching and Learning in Medicine</i> , 2001 , 13, 183-91	3.4	13

8	Comprehensive transcript analysis in small quantities of mRNA by SAGE-lite. <i>Nucleic Acids Research</i> , 1999 , 27, e39	20.1	80
7	Phase II Trial of the Antiestrogen Toremifene for Androgen-Independent Prostate Cancer. <i>Prostate Journal</i> , 1999 , 1, 185-189		1
6	The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 3320-3	11.5	668
5	Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. <i>Urology</i> , 1997 , 49, 913-20	1.6	75
4	A mutation of the glucocorticoid receptor in primary cortisol resistance. <i>Journal of Clinical Investigation</i> , 1993 , 91, 1918-25	15.9	147
3	Variability of Accessory Proteins Rules the SARS-CoV-2 Pathogenicity		4
2	An Issue of Concern: Unique Truncated ORF8 Protein Variants of SARS-CoV-2		1
1	RNA expression classifiers from a model of breast epithelial cell organization to predict pathological complete response in triple negative breast cancer		1